1,400 more Olongapo residents jabbed vs COVID-19 | Inquirer News

1,400 more Olongapo residents jabbed vs COVID-19

Mass vaccination in Olongapo City

The mass vaccination in Olongapo City continues as more residents on the priority list troop to the vaccination site at the SMX Convention Center of SM Olongapo Central. (Photo courtesy of Olongapo City Information Center)

OLONGAPO CITY––At least 1,400 more residents in this city got vaccinated against COVID-19.

The city public information center said on Tuesday, Aug. 10, that at least 700 residents got their first dose of Sinovac and 700 their second dose of AstraZeneca.

Article continues after this advertisement

About 24,000 residents had been vaccinated against COVID-19, and some 20,000 of them were fully inoculated.

FEATURED STORIES

The local government has also administered 7,800 single-dose Janssen vaccines made by Johnson & Johnson.

The city targets to achieve herd immunity by vaccinating 182,000 of its 260,000 population.

lzb
Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.

TAGS: COVID-19, Olongapo City, Regions, Vaccination

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.